Premier Alternatives

Kestrel Therapeutics

Allston, MA · Founded 2020 · Privately Held (backing)

Developer of oncological drugs designed to treat RAS-driven cancers and bring a new therapy to cancer's frequently mutated oncogenic target. Kestrel Therapeutics is based in Allston, MA and was founded in 2020. Its last reported valuation was $17.7 million in Jan 2022. It has raised $20.7 million across 3 recorded rounds; the latest was a $5 million early-stage round in Jul 2025.

Last reported valuation
$17.7M
Oct 2026
Priced at
—
Total raised
$20.7M
Last round
Early Stage VC
Jul 2025

Kestrel Therapeutics key facts

as of Oct 2026
  • Developer of oncological drugs designed to treat RAS-driven cancers and bring a new therapy to cancer's frequently mutated oncogenic target.
  • Kestrel Therapeutics is valued at approximately $17.7M as of Oct 2026 (last reported valuation).
  • It has raised $20.7M across 3 recorded rounds; the latest was Early Stage VC ($5.0M) in Jul 2025.
  • Notable investors include Harvard Innovation Launch Lab, S32, Cormorant Asset Management, Pfizer Ventures, Santé Ventures.
  • Kestrel Therapeutics has filed 4 Form Ds with the SEC since 2021, most recently Aug 2025 ($5.0M sold to 6 investors).
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$17.7M

Kestrel Therapeutics's last reported valuation, Jan 2022. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Kestrel Therapeutics with a free account
  • ·Watch Kestrel Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Kestrel Therapeutics funding rounds

3 rounds
Jul 2025Early Stage VC$5.0MSEC filing▮
Feb 2025Early Stage VC$8.0MSEC filing▮
Dec 2021Early Stage VC$7.5MSEC filing▮
Full funding history →

Kestrel Therapeutics valuation

Kestrel Therapeutics's last reported valuation was $17.7 million in Jan 2022. No priced round, secondary trade or fund mark has surfaced since.

How much has Kestrel Therapeutics raised?

Kestrel Therapeutics has raised $20.7 million across 3 recorded rounds since 2021. The largest was an $8 million early-stage round in Feb 2025; the most recent was a $5 million early-stage round in Jul 2025.

Kestrel Therapeutics has filed 4 Form Ds with the SEC since 2021, most recently in Aug 2025 ($5 million sold to 6 investors).

Kestrel Therapeutics investors

5 investors are on record for Kestrel Therapeutics, including Harvard Innovation Launch Lab, S32, Cormorant Asset Management and Pfizer Ventures. The early-stage round in Jul 2025 drew 6 investors.

About Kestrel Therapeutics

Developer of oncological drugs designed to treat RAS-driven cancers and bring a new therapy to cancer's frequently mutated oncogenic target. The company develops molecules active regardless of RAS isoform, mutation, or tumor histology, enabling healthcare professionals to cure patients suffering from cancer.

Sector
Healthcare
HQ
Allston, MA, United States
Founded
2020
Employees
28
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.